Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341560 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
A Phase 2 study, sponsored by Quark Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 732
- Enrollment target
NCT02341560 is a Phase 2 study that was terminated before completion, run by Quark Pharmaceuticals. The registered enrollment target is 732 participants.
The verdict
NCT02341560, a Phase 2 study, was terminated before completion, sponsored by Quark Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 732 participants
- Enrollment target
Study Summary
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI-1007.
Interventions
- DRUG QPI-1007 Injection - 1.5 mg
- DRUG QPI-1007 Injection - 3.0 mg
- OTHER Sham Injection Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2016-02-24 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341560
The ClinicalTrials.gov registry entry for NCT02341560 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 732 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which QPI-1007 Injection - 1.5 mg is the first listed.
NCT02341560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02341560 about?
NCT02341560 is a clinical study titled "Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)". This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI...
What is the current status of trial NCT02341560?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 732 participants. The study started on 2016-02-24. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT02341560?
The interventions under investigation include: QPI-1007 Injection - 1.5 mg (DRUG), QPI-1007 Injection - 3.0 mg (DRUG), Sham Injection Procedure (OTHER).
Who is sponsoring clinical trial NCT02341560?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.